Changes of protein expression in prostate cancer having lost its androgen sensitivity

Gergely Bánfi, Ivett Teleki, P. Nyírády, Attila Keszthelyi, I. Romics, A. Fintha, T. Krenács, B. Szende

Research output: Article

1 Citation (Scopus)

Abstract

Objective: The majority of prostate cancers require androgen hormones for growth, and androgen ablation is an important part of the systemic treatment of advanced prostate cancer. Nevertheless, most of these cancers eventually relapse as they become less sensitive to androgen ablation and anti-androgen treatment. Elucidating the molecular events that are responsible for the conversion of androgen-sensitive cancers to androgen-refractory tumors may reveal new therapeutic opportunities. Methods: In the present study, we investigated nine androgen-sensitive and nine androgen-refractory prostate cancer samples to evaluate the expression levels of 10 selected proteins that have been implicated in oncogenesis and cancer progression. Results: Our immunohistochemical data show that three of the investigated proteins (i.e., minichromosome maintenance-2, methylguanine-DNA methyltransferase, and androgen receptor) are expressed at significantly different levels in the androgen-refractory cancer samples than in the androgen-sensitive tumors, whereas the expression levels of the seven other studied proteins (i.e., β-catenin, p27, p21, p16, Ki67, hypoxia-inducible factor 1 alpha, and geminin) are not significantly different regarding the two groups. Conclusions: Our data suggest that the increased expression of minichromosome maintenance-2 and decreased expression of methylguanine-DNA methyltransferase related to androgen receptor are indicative of the androgen-refractory stage in prostate cancer. Further studies are required to determine whether these expression changes play a causative role in the transition of androgen-sensitive to androgen-refractory prostate cancer.

Original languageEnglish
Pages (from-to)1149-1154
Number of pages6
JournalInternational Urology and Nephrology
Volume47
Issue number7
DOIs
Publication statusPublished - júl. 27 2015

Fingerprint

Androgens
Prostatic Neoplasms
Proteins
Neoplasms
Methyltransferases
Androgen Receptors
Geminin
Minichromosome Maintenance Proteins
Hypoxia-Inducible Factor 1
Catenins
Growth Hormone
Carcinogenesis
Maintenance
Recurrence

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Changes of protein expression in prostate cancer having lost its androgen sensitivity. / Bánfi, Gergely; Teleki, Ivett; Nyírády, P.; Keszthelyi, Attila; Romics, I.; Fintha, A.; Krenács, T.; Szende, B.

In: International Urology and Nephrology, Vol. 47, No. 7, 27.07.2015, p. 1149-1154.

Research output: Article

@article{eecf813f5c6b498489517d83c3d3601b,
title = "Changes of protein expression in prostate cancer having lost its androgen sensitivity",
abstract = "Objective: The majority of prostate cancers require androgen hormones for growth, and androgen ablation is an important part of the systemic treatment of advanced prostate cancer. Nevertheless, most of these cancers eventually relapse as they become less sensitive to androgen ablation and anti-androgen treatment. Elucidating the molecular events that are responsible for the conversion of androgen-sensitive cancers to androgen-refractory tumors may reveal new therapeutic opportunities. Methods: In the present study, we investigated nine androgen-sensitive and nine androgen-refractory prostate cancer samples to evaluate the expression levels of 10 selected proteins that have been implicated in oncogenesis and cancer progression. Results: Our immunohistochemical data show that three of the investigated proteins (i.e., minichromosome maintenance-2, methylguanine-DNA methyltransferase, and androgen receptor) are expressed at significantly different levels in the androgen-refractory cancer samples than in the androgen-sensitive tumors, whereas the expression levels of the seven other studied proteins (i.e., β-catenin, p27, p21, p16, Ki67, hypoxia-inducible factor 1 alpha, and geminin) are not significantly different regarding the two groups. Conclusions: Our data suggest that the increased expression of minichromosome maintenance-2 and decreased expression of methylguanine-DNA methyltransferase related to androgen receptor are indicative of the androgen-refractory stage in prostate cancer. Further studies are required to determine whether these expression changes play a causative role in the transition of androgen-sensitive to androgen-refractory prostate cancer.",
keywords = "Androgen receptor, Castration resistant, Geminin, MCM2, MGMT, Prostate carcinoma",
author = "Gergely B{\'a}nfi and Ivett Teleki and P. Ny{\'i}r{\'a}dy and Attila Keszthelyi and I. Romics and A. Fintha and T. Kren{\'a}cs and B. Szende",
year = "2015",
month = "7",
day = "27",
doi = "10.1007/s11255-015-0985-1",
language = "English",
volume = "47",
pages = "1149--1154",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - Changes of protein expression in prostate cancer having lost its androgen sensitivity

AU - Bánfi, Gergely

AU - Teleki, Ivett

AU - Nyírády, P.

AU - Keszthelyi, Attila

AU - Romics, I.

AU - Fintha, A.

AU - Krenács, T.

AU - Szende, B.

PY - 2015/7/27

Y1 - 2015/7/27

N2 - Objective: The majority of prostate cancers require androgen hormones for growth, and androgen ablation is an important part of the systemic treatment of advanced prostate cancer. Nevertheless, most of these cancers eventually relapse as they become less sensitive to androgen ablation and anti-androgen treatment. Elucidating the molecular events that are responsible for the conversion of androgen-sensitive cancers to androgen-refractory tumors may reveal new therapeutic opportunities. Methods: In the present study, we investigated nine androgen-sensitive and nine androgen-refractory prostate cancer samples to evaluate the expression levels of 10 selected proteins that have been implicated in oncogenesis and cancer progression. Results: Our immunohistochemical data show that three of the investigated proteins (i.e., minichromosome maintenance-2, methylguanine-DNA methyltransferase, and androgen receptor) are expressed at significantly different levels in the androgen-refractory cancer samples than in the androgen-sensitive tumors, whereas the expression levels of the seven other studied proteins (i.e., β-catenin, p27, p21, p16, Ki67, hypoxia-inducible factor 1 alpha, and geminin) are not significantly different regarding the two groups. Conclusions: Our data suggest that the increased expression of minichromosome maintenance-2 and decreased expression of methylguanine-DNA methyltransferase related to androgen receptor are indicative of the androgen-refractory stage in prostate cancer. Further studies are required to determine whether these expression changes play a causative role in the transition of androgen-sensitive to androgen-refractory prostate cancer.

AB - Objective: The majority of prostate cancers require androgen hormones for growth, and androgen ablation is an important part of the systemic treatment of advanced prostate cancer. Nevertheless, most of these cancers eventually relapse as they become less sensitive to androgen ablation and anti-androgen treatment. Elucidating the molecular events that are responsible for the conversion of androgen-sensitive cancers to androgen-refractory tumors may reveal new therapeutic opportunities. Methods: In the present study, we investigated nine androgen-sensitive and nine androgen-refractory prostate cancer samples to evaluate the expression levels of 10 selected proteins that have been implicated in oncogenesis and cancer progression. Results: Our immunohistochemical data show that three of the investigated proteins (i.e., minichromosome maintenance-2, methylguanine-DNA methyltransferase, and androgen receptor) are expressed at significantly different levels in the androgen-refractory cancer samples than in the androgen-sensitive tumors, whereas the expression levels of the seven other studied proteins (i.e., β-catenin, p27, p21, p16, Ki67, hypoxia-inducible factor 1 alpha, and geminin) are not significantly different regarding the two groups. Conclusions: Our data suggest that the increased expression of minichromosome maintenance-2 and decreased expression of methylguanine-DNA methyltransferase related to androgen receptor are indicative of the androgen-refractory stage in prostate cancer. Further studies are required to determine whether these expression changes play a causative role in the transition of androgen-sensitive to androgen-refractory prostate cancer.

KW - Androgen receptor

KW - Castration resistant

KW - Geminin

KW - MCM2

KW - MGMT

KW - Prostate carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84933180450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933180450&partnerID=8YFLogxK

U2 - 10.1007/s11255-015-0985-1

DO - 10.1007/s11255-015-0985-1

M3 - Article

VL - 47

SP - 1149

EP - 1154

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 7

ER -